Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of more news that didn’t make the cut over the last week. 

  • German biotech AiCuris reported positive Phase I results from trialing its inactivated parapoxvirus anti-hepatitis B candidate 
  • US researchers behind Luxterna gene therapy for hereditary blindness win European António Champalimaud Vision Award 2018 for advances to prevent blindness
  • Austrian Ares Genetics, a subsidiary of Curetis, is developing an infectious disease test to cover nearly any pathogen that will be powered by artificial intelligence
  • UK-based Azeria Therapeutics, a Cancer research UK spinout, raised €4.5M in series A financing to target hormone-resistant breast and prostate cancer with its ‘pioneer factor’ inhibiting drug candidates
  • Anergis, a Swiss biotech, announced positive Phase II results for its birch pollen allergy vaccine and the company also said it will start development of a new generation of its allergy vaccines
  • UK-based Summit Therapeutics said it is developing a new candidate antibiotic, with promising early results, to fight against drug-resistant gonorrhea
  • Summit also announced its discovery of a range of new antibiotics aimed at treating superbugs such as Staphylococcus aureus and Klebsiella pneumoniae, which it plans to test further
  • French artificial pancreas competitor Cellnovo launched its Gen 3 mobile diabetes management system, which allows insulin pump control via a bluetooth connection with a closed android phone system
  • Jersey-based Novocure said its electronic fields technology extended survival in mesothelioma patients by more than 6 months in its Phase II trial
  • The Novo REPAIR Fund, set up by diabetes giant Novo Nordisk earlier this year, will invest up to €10.2M in Swiss biotech Polyphor to help develop its outer membrane protein targeting antibiotics aimed at Gram-negative superbugs
  • The Gilead–Galapagos collaboration achieved positive Phase II results for the US and Dutch companies in a study of their JAK inhibitor filgotinib in patients with ankylosing spondylitis
  • Russian scientists have successfully tested 3D printed, completely biodegradable tibia implants in animals, an advance they hope will reduce the time it takes for new bone tissue to form after surgical repair

Images: E. Resko

Previous post

Update: Non-Invasive Glucose Monitoring Device Moves Forward With Series B Funding

Next post

Cambridge Biotech Targets Artificial Pancreas Market With Fast Insulin and Stable Glucagon

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.